• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康相关生活质量在脊髓小脑共济失调患者中的研究: EQ-5D-3L 的验证研究。

Health-Related Quality of Life in Patients with Spinocerebellar Ataxia: a Validation Study of the EQ-5D-3L.

机构信息

Translational Health Care Research, German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany.

German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

出版信息

Cerebellum. 2024 Jun;23(3):1020-1030. doi: 10.1007/s12311-023-01597-3. Epub 2023 Sep 15.

DOI:10.1007/s12311-023-01597-3
PMID:37713052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11102408/
Abstract

Although health-related quality of life (HRQoL) has developed into a crucial outcome parameter in clinical research, evidence of the EQ-5D-3L validation performance is lacking in patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. The objective of this study is to assess the acceptability, validity, reliability, and responsiveness of the EQ-5D-3L. For n = 842 predominantly European SCA patients of two longitudinal cohort studies, the EQ-5D-3L, PHQ-9 (Patient Health Questionnaire), and ataxia-specific clinical assessments (SARA: Scale for Assessment and Rating of Ataxia; ADL: activities of daily living as part of Friedreich's Ataxia Rating Scale; INAS: Inventory of Non-Ataxia Signs) were assessed at baseline and multiple annual follow-ups. The EQ-5D-3L was evaluated regarding acceptability, distribution properties, convergent and known-groups validity, test-retest reliability, and effect size measures to analyze health changes. The non-item response was low (EQ-5D-3L index: 0.8%; EQ-VAS: 3.4%). Ceiling effects occurred in 9.9% (EQ-5D-3L) and 3.0% (EQ-VAS) with a mean EQ-5D-3L index of 0.65 ± 0.21. In total, convergent validity showed moderate to strong Spearman's rho (r > 0.3) coefficients comparing EQ-5D-3L and EQ-VAS with PHQ-9, SARA, ADL, and INAS. EQ-5D-3L could discriminate between groups of age, SARA, ADL, and INAS. Intra-class correlation coefficients (EQ-5D-3L: 0.95/EQ-VAS: 0.88) and Kappa statistics (range 0.44 to 0.93 for EQ-5D-3L items) indicated tolerable reliability. EQ-5D-3L shows small (effect size < 0.3) to moderate (effect size 0.3-0.59) health changes regarding ataxia severity. The analysis confirms an acceptable, reliable, valid, and responsive recommended EQ-5D-3L in SCA patients, measuring the HRQoL adequately, besides well-established clinical instruments.

摘要

尽管健康相关生活质量(HRQoL)已成为临床研究中的重要结果参数,但在脊髓小脑共济失调(SCA)类型 1、2、3 和 6 患者中,缺乏 EQ-5D-3L 验证性能的证据。本研究旨在评估 EQ-5D-3L 的可接受性、有效性、可靠性和反应性。对于来自两个纵向队列研究的 n = 842 名主要为欧洲的 SCA 患者,在基线和多次年度随访时评估了 EQ-5D-3L、PHQ-9(患者健康问卷)和特定于共济失调的临床评估(SARA:共济失调评估和评分量表;ADL:作为弗里德里希共济失调评分量表一部分的日常生活活动;INAS:非共济失调体征量表)。EQ-5D-3L 的评估涉及可接受性、分布特性、收敛性和已知群体有效性、测试-重测可靠性以及用于分析健康变化的效应量措施。非项目反应率较低(EQ-5D-3L 指数:0.8%;EQ-VAS:3.4%)。9.9%(EQ-5D-3L)和 3.0%(EQ-VAS)出现天花板效应,平均 EQ-5D-3L 指数为 0.65 ± 0.21。总体而言,EQ-5D-3L 和 EQ-VAS 与 PHQ-9、SARA、ADL 和 INAS 之间的收敛效度显示出中度至高度 Spearman's rho(r > 0.3)系数。EQ-5D-3L 能够区分年龄、SARA、ADL 和 INAS 组。内部一致性系数(EQ-5D-3L:0.95/EQ-VAS:0.88)和 Kappa 统计量(EQ-5D-3L 项的范围为 0.44 至 0.93)表明可靠性可接受。EQ-5D-3L 显示出与共济失调严重程度相关的较小(效应量<0.3)至中度(效应量 0.3-0.59)的健康变化。分析证实,EQ-5D-3L 在 SCA 患者中具有可接受的、可靠的、有效的和有反应的推荐使用,除了已建立的临床仪器外,还能充分衡量 HRQoL。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/11102408/f450a75e3a50/12311_2023_1597_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/11102408/f450a75e3a50/12311_2023_1597_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc9/11102408/f450a75e3a50/12311_2023_1597_Fig1_HTML.jpg

相似文献

1
Health-Related Quality of Life in Patients with Spinocerebellar Ataxia: a Validation Study of the EQ-5D-3L.健康相关生活质量在脊髓小脑共济失调患者中的研究: EQ-5D-3L 的验证研究。
Cerebellum. 2024 Jun;23(3):1020-1030. doi: 10.1007/s12311-023-01597-3. Epub 2023 Sep 15.
2
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.欧洲弗里德里希共济失调转化研究联合会(EFACTS)的进展特征:一项为期 2 年的队列研究。
Lancet Neurol. 2016 Dec;15(13):1346-1354. doi: 10.1016/S1474-4422(16)30287-3.
3
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression.比较 ADHD、焦虑和/或抑郁儿童和青少年使用通用儿科健康相关生活质量工具的心理计量学性能。
Pharmacoeconomics. 2024 Jun;42(Suppl 1):57-77. doi: 10.1007/s40273-024-01354-2. Epub 2024 Feb 8.
4
The feasibility, repeatability, validity and responsiveness of the EQ-5D-3L in Krio for patients with stroke in Sierra Leone.塞拉利昂中风患者克里奥语版 EQ-5D-3L 的可行性、可重复性、有效性和反应度。
Health Qual Life Outcomes. 2024 Mar 28;22(1):29. doi: 10.1186/s12955-024-02246-x.
5
Comparison of the measurement properties and consistency between the EQ-5D-3L and EQ-5D-Y-3L in adolescents aged 15-17 in China.中国 15-17 岁青少年中 EQ-5D-3L 与 EQ-5D-Y-3L 的测量特性和一致性比较。
Health Qual Life Outcomes. 2024 Jul 29;22(1):59. doi: 10.1186/s12955-024-02275-6.
6
The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.在测量等待全髋关节置换术或全膝关节置换术的患者的健康相关生活质量方面,EQ-5D-5L 优于 -3L 版本。
Clin Orthop Relat Res. 2019 Jul;477(7):1632-1644. doi: 10.1097/CORR.0000000000000662.
7
Factors Influencing Health-Related Quality of Life of Patients with Spinocerebellar Ataxia.影响脊髓小脑共济失调患者健康相关生活质量的因素。
Cerebellum. 2024 Aug;23(4):1466-1477. doi: 10.1007/s12311-024-01657-2. Epub 2024 Jan 27.
8
Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients.泰国糖尿病患者中EQ-5D-5L与EQ-5D-3L相比的测量属性
Health Qual Life Outcomes. 2015 Feb 6;13:14. doi: 10.1186/s12955-014-0203-3.
9
Validity and reliability of the EQ-5D-3L (a generic preference-based instrument used for calculating quality-adjusted life -years) for patients with type 2 diabetes in Iran.伊朗 2 型糖尿病患者使用 EQ-5D-3L(一种用于计算质量调整生命年的通用偏好量表)的有效性和可靠性。
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):319-324. doi: 10.1016/j.dsx.2021.01.009. Epub 2021 Jan 14.
10
Psychometric properties of the EuroQol Five Dimensional Questionnaire (EQ-5D-3L) in caregivers of autistic children.《自闭症儿童照顾者的欧洲五维健康量表(EQ-5D-3L)的心理测量特性》
Qual Life Res. 2013 Dec;22(10):2909-20. doi: 10.1007/s11136-013-0423-8. Epub 2013 Apr 25.

引用本文的文献

1
Content Validity of the Spinocerebellar Ataxia Composite Score as a Measure of Disease Progression in Patients with Spinocerebellar Ataxia.脊髓小脑共济失调综合评分作为脊髓小脑共济失调患者疾病进展指标的内容效度
Cerebellum. 2025 Sep 1;24(5):146. doi: 10.1007/s12311-025-01896-x.
2
Impact of rehabilitation on quality of life in patients with degenerative cerebellar ataxias using structural equation modeling.使用结构方程模型评估康复对退行性小脑共济失调患者生活质量的影响。
Sci Rep. 2025 Jul 1;15(1):21997. doi: 10.1038/s41598-025-01990-4.
3
Longitudinal description of health-related quality of life and depressive symptoms in polyQ spinocerebellar ataxia patients.

本文引用的文献

1
Patient-reported, health economic and psychosocial outcomes in patients with Friedreich ataxia (PROFA): protocol of an observational study using momentary data assessments via mobile health app.弗里德里希共济失调患者的患者报告、健康经济和心理社会结局(PROFA):使用移动健康应用程序进行即时数据评估的观察性研究方案。
BMJ Open. 2023 Aug 1;13(8):e075736. doi: 10.1136/bmjopen-2023-075736.
2
Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity.脊髓小脑性共济失调 3 型的生活方式特征及其与疾病严重程度的关联。
Mov Disord. 2022 Feb;37(2):405-410. doi: 10.1002/mds.28844. Epub 2021 Oct 29.
3
多聚谷氨酰胺脊髓小脑共济失调患者健康相关生活质量和抑郁症状的纵向描述
J Neurol. 2025 Apr 9;272(5):323. doi: 10.1007/s00415-025-13024-0.
4
Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.外泌体在调节用于神经退行性疾病生物标志物的微小RNA中的作用
Mol Neurobiol. 2025 Jun;62(6):7576-7596. doi: 10.1007/s12035-025-04733-8. Epub 2025 Feb 7.
5
Content Validity of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.脊髓小脑共济失调患者中Friedreich共济失调评定量表的内容效度
Neurol Ther. 2025 Apr;14(2):547-563. doi: 10.1007/s40120-024-00704-8. Epub 2025 Jan 15.
6
Health-Related Quality of Life in Patients with Friedreich Ataxia Using Mobility Assistive Technologies: Limited Fit of the EQ-5D-3L Mobility Dimension.使用移动辅助技术的弗里德赖希共济失调患者的健康相关生活质量:EQ-5D-3L移动维度的拟合度有限。
Neurol Ther. 2025 Feb;14(1):379-398. doi: 10.1007/s40120-024-00694-7. Epub 2024 Dec 30.
7
Factors Influencing Health-Related Quality of Life of Patients with Spinocerebellar Ataxia.影响脊髓小脑共济失调患者健康相关生活质量的因素。
Cerebellum. 2024 Aug;23(4):1466-1477. doi: 10.1007/s12311-024-01657-2. Epub 2024 Jan 27.
Quality of Life since Pre-Ataxic Phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
脊髓小脑性共济失调 3 型/马查多-约瑟夫病前共济失调阶段的生活质量。
Cerebellum. 2022 Apr;21(2):297-305. doi: 10.1007/s12311-021-01299-8. Epub 2021 Jul 6.
4
Development and Validation of a Patient-Reported Outcome Measure of Ataxia.开发和验证一种用于评估共济失调的患者报告结局测量工具。
Mov Disord. 2021 Oct;36(10):2367-2377. doi: 10.1002/mds.28670. Epub 2021 Jun 11.
5
The performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings.EQ-5D-3L 在医院和社区环境中筛查焦虑和抑郁症状的性能。
Health Qual Life Outcomes. 2021 Mar 19;19(1):96. doi: 10.1186/s12955-021-01731-x.
6
Discordance Between Patient-Reported Outcomes and Physician-Rated Motor Symptom Severity in Early-to-Middle-Stage Spinocerebellar Ataxia Type 3.脊髓小脑性共济失调 3 型早中期患者报告结局与医师评定运动症状严重程度的差异。
Cerebellum. 2021 Dec;20(6):887-895. doi: 10.1007/s12311-021-01252-9. Epub 2021 Mar 10.
7
Psychometric Validation of the EQ-5D-3L in Patients with Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Complex (MAC).复杂型(MAC)非结核分枝杆菌(NTM)肺病患者中EQ-5D-3L量表的心理测量学验证
Patient Relat Outcome Meas. 2021 Feb 25;12:45-54. doi: 10.2147/PROM.S272075. eCollection 2021.
8
Acceptability and Validity of the EQ-5D in Patients Living With Dementia.痴呆患者的 EQ-5D 的可接受性和有效性。
Value Health. 2020 Jun;23(6):760-767. doi: 10.1016/j.jval.2020.01.022. Epub 2020 May 22.
9
Natural history of most common spinocerebellar ataxia: a systematic review and meta-analysis.最常见的脊髓小脑共济失调的自然史:系统评价和荟萃分析。
J Neurol. 2021 Aug;268(8):2749-2756. doi: 10.1007/s00415-020-09815-2. Epub 2020 Apr 7.
10
A Comparison of the EQ-5D-3L and EQ-5D-5L.EQ-5D-3L 与 EQ-5D-5L 的比较。
Pharmacoeconomics. 2020 Jun;38(6):575-591. doi: 10.1007/s40273-020-00893-8.